Moleculin Biotech (NASDAQ:MBRX) Earning Somewhat Positive Media Coverage, Report Finds

News articles about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Moleculin Biotech earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.7303750675033 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ MBRX opened at $1.80 on Monday. The firm has a market capitalization of $46.38, a price-to-earnings ratio of -3.83 and a beta of -1.44. Moleculin Biotech has a 52-week low of $0.71 and a 52-week high of $3.75.

A number of analysts have issued reports on MBRX shares. Roth Capital started coverage on shares of Moleculin Biotech in a report on Wednesday, December 20th. They issued a “buy” rating and a $8.00 price target on the stock. ValuEngine upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

ILLEGAL ACTIVITY WARNING: “Moleculin Biotech (NASDAQ:MBRX) Earning Somewhat Positive Media Coverage, Report Finds” was published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/04/02/moleculin-biotech-mbrx-getting-somewhat-favorable-news-coverage-accern-reports/2002441.html.

About Moleculin Biotech

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.